Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSE:6090's Forward Dividend Yield % is ranked better than 86.89% of 61
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.92
vs TSE:6090: 5.58
Human Metabolome Technologies (TSE:6090) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Human Metabolome Technologies Forward Dividend Yield % Related Terms
TSE:6090 vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Forward Dividend Yield % falls into.
Human Metabolome Technologies Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Human Metabolome Technologies Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
JPY 18.000000
2026-06-29
2026-06-30
2026-09-03
Cash Dividend
semi-annually
JPY:JPY 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 5.58% mean?
Human Metabolome Technologies (TSE:6090) has a Forward Dividend Yield % of 5.58% as of Aug. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Human Metabolome Technologies and its competitors. According to the industry distribution chart, Human Metabolome Technologies ranks #8 out of 61 companies in the Medical Diagnostics & Research industry, placing it in the top 13.1%.
Is Human Metabolome Technologies' Forward Dividend Yield % too high?
Human Metabolome Technologies' current Forward Dividend Yield % is 5.58%. The Medical Diagnostics & Research industry median Forward Dividend Yield % is 1.92. Human Metabolome Technologies' value of 5.58% is 190.6% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #8 out of 61 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #8 out of 61 companies for Forward Dividend Yield %. This places Human Metabolome Technologies in the top 13% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 1.92. Human Metabolome Technologies' value of 5.58% is 190.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.92, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Forward Dividend Yield % of 5.58% is 190.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Forward Dividend Yield % is 5.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円693.69, compared to a current price of 円625.00 — trading 9.9% below its estimated fair value. The current Forward Dividend Yield % is 5.58% and 190.6% above the Medical Diagnostics & Research industry median of 1.92. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Forward Dividend Yield % is 5.58% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円625.00 is trading 9.9% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.
Key valuation signals for TSE:6090:
Forward Dividend Yield %: 5.58%
GF Value™: 円693.69 vs. price of 円625.00 (9.9% below fair value)
Industry Position: 190.6% above the Medical Diagnostics & Research median (#8 of 61)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
